Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.03.433704: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding Lung histology: Serial 4 μm sections of the left lobe were cut and stained with haematoxylin and eosin (H&E) and Masson’s trichrome and evaluated independently by a veterinary pathologist and a pulmonary immunologist both of whom were blinded to the experimental treatment. Power Analysis not detected. Sex as a biological variable Female, 11-13 week old C57BL/6 mice (Charles River Laboratories) were administered one intranasal 40 μL dose of bleomycin sulphate (7.5 or 11.25 units/kg) or phosphate buffered saline (PBS) vehicle control under light isoflurane anaesthesia. Table 2: Resources
… SciScore for 10.1101/2021.03.03.433704: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding Lung histology: Serial 4 μm sections of the left lobe were cut and stained with haematoxylin and eosin (H&E) and Masson’s trichrome and evaluated independently by a veterinary pathologist and a pulmonary immunologist both of whom were blinded to the experimental treatment. Power Analysis not detected. Sex as a biological variable Female, 11-13 week old C57BL/6 mice (Charles River Laboratories) were administered one intranasal 40 μL dose of bleomycin sulphate (7.5 or 11.25 units/kg) or phosphate buffered saline (PBS) vehicle control under light isoflurane anaesthesia. Table 2: Resources
Experimental Models: Organisms/Strains Sentences Resources Female, 11-13 week old C57BL/6 mice (Charles River Laboratories) were administered one intranasal 40 μL dose of bleomycin sulphate (7.5 or 11.25 units/kg) or phosphate buffered saline (PBS) vehicle control under light isoflurane anaesthesia. C57BL/6suggested: NoneSoftware and Algorithms Sentences Resources Flow cytometry data were acquired on a BD Fortessa and analysed using FlowJo (version10, BD Biosciences). FlowJosuggested: (FlowJo, RRID:SCR_008520)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However we recognise its limitations: immune responses to bleomycin and SARS-CoV-2 are not identical, neither within the lungs nor systemically. Furthermore, our experiments were conducted exclusively in female mice aged 11-13 weeks. There is some evidence that young mice are less responsive to bleomycin than older mice (36) and it is possible that male mice would respond differently to bleomycin, LDLR or both. Furthermore, it is well established that the risk of severe COVID-19 lung disease is much greater in older patients (37), and that males are at higher risk of poor outcomes (38). Having identified bodyweight as a clinically relevant primary endpoint that correlates with the severity of bleomycin-induced pneumonitis and the associated systemic inflammatory response (39), we observed wide variation between mice in terms of rapidity and severity of weight loss, and subsequent recovery. Despite the challenges posed by this variability, our findings support the hypothesis that LDLR, delivered at a time when early histological and immunological features of lung inflammation are apparent, increases the likelihood of recovery in a subset of mice (approximately 25%). Subsequent analyses indicated that mice with moderate lung disease (measured either by lower rates of weight loss or by less marked imaging changes on CT scans) were more likely to respond to LDLR than those with severe pneumonitis. These bodyweight data are supported by histological, radiological and immunological...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
